Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Blood (2024) 144 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2024-211527

Published: 2024

Journal Articles

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Ramon Garcia-Sanz, Anna Sureda Balari, Eva Domingo Domenech, Francisco Javier Capote Huelva, Antonio Gutierrez, Antonia Rodriguez Izquierdo, Marta Grande De Domingo, Lourdes Baeza

Blood (2024) 144 (Supplement 1): 2376.

https://doi.org/10.1182/blood-2024-193585

Published: 2024

Journal Articles

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

Ana Jiménez Ubieto, Alejandro Martín-Muñoz, Ricardo Errazquin, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Esther Parra, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Teresa Cedena Romero, Joaquin Martínez-López, Rosa Ayala, Inmaculada Rapado

Blood (2024) 144 (Supplement 1): 6227.

https://doi.org/10.1182/blood-2024-207390

Published: 2024

Journal Articles

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1674.2.

https://doi.org/10.1182/blood-2024-203060

Published: 2024

Journal Articles

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Alejandro Martín-Muñoz, Ana Jiménez Ubieto, Yanira Ruiz-Heredia, Laura Rufián, Margarita Rodríguez, Tycho Baumann, Antonia Rodriguez Izquierdo, Maria Poza Santaella, Daniel Gil Alos, Pilar Sarandeses, Enrique Revilla, Gloria Figaredo, Ricardo Errazquin, Inmaculada Rapado, Rosa Ayala, Santiago Barrio, Joaquin Martínez-López

Blood (2024) 144 (Supplement 1): 6204.

https://doi.org/10.1182/blood-2024-206966

Published: 2024

Journal Articles

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 855.

https://doi.org/10.1182/blood-2023-177588

Published: 2023

Journal Articles

Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital

Ana Jimenez Ubieto, Rodrigo Gil Manso, Daniel Gil Alós, María Poza Santaella, Tycho Baumann, Antonia Rodriguez Izquierdo, Marina Quesada Sánchez, Pilar Martinez Sanchez, Carlos Grande, Renata Garcia Gigorro, Maria Calbacho, Santiago Barrio, Joaquin Martinez Lopez

Blood (2023) 142 (Supplement 1): 4490.

https://doi.org/10.1182/blood-2023-189478

Published: 2023

Journal Articles

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Maria Poza Santaella, Rodrigo Íñiguez, Irene Zamanillo, Tycho S. Baumann, Antonia Rodriguez Izquierdo, Enrique Revilla, Sandra Gomez Rojas, Gloria Perez Segura, Pilar Martinez Sanchez, Carlos Grande, Pilar Sarandeses, Santiago Barrio, Maria Calbacho, Rosa Ayala, Joaquin Martinez-Lopez, Ana Jimenez Ubieto

Blood (2023) 142 (Supplement 1): 4405.

https://doi.org/10.1182/blood-2023-189161

Published: 2023

Journal Articles

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Blood (2022) 140 (Supplement 1): 3514–3515.

https://doi.org/10.1182/blood-2022-166372

Published: 2022

Journal Articles

Usability and Performance Testing of Pointcheck™: A Noninvasive Neutropenia Screening Device for Chemotherapy Outpatients

Ganimete Lamaj, Alberto Pablo-Trinidad, Ian Butterworth, Nolan Bell, Ryan Benasutti, Antonio Verdone, Aurelien Bourquard, Alvaro Sanchez-Ferro, Carlos Castro-Gonzalez, Antonia Rodriguez Izquierdo, Tycho Baumann, Elizabeth Pottier, Joaquín Martínez-López, John Mark Sloan

Blood (2021) 138 (Supplement 1): 4924.

https://doi.org/10.1182/blood-2021-150932

Published: 2021

Journal Articles

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Anna Sureda, Ana Pilar González, Javier Núñez, Javier Briones, Fátima De la Cruz, Domingo Domenech Eva, Francisca Maria Hernandez, María José Terol, Elena Amutio, Raul Cordoba, Carmen Martínez, Miriam Moreno, Antonia Rodriguez Izquierdo, Raquel Del Campo, Richard Greil, Samuel Romero, Ramón Garcia-Sanz

Blood (2021) 138 (Supplement 1): 2459.

https://doi.org/10.1182/blood-2021-150200

Published: 2021

Journal Articles

Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH

Blood (2021) 138 (Supplement 1): 4491.

https://doi.org/10.1182/blood-2021-152376

Published: 2021

Journal Articles

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Nancy L. Bartlett, Alex F. Herrera, Eva Domingo-Domenech, Amitkumar Mehta, Andres Forero-Torres, Ramon Garcia-Sanz, Philippe Armand, Sumana Devata, Antonia Rodriguez Izquierdo, Izidore S. Lossos, Craig Reeder, Taimur Sher, Robert Chen, Sylvia E. Schwarz, Leila Alland, Andras Strassz, Kim Prier, Cassandra Choe-Juliak, Stephen M. Ansell

Blood (2020) 136 (21): 2401–2409.

https://doi.org/10.1182/blood.2019004701

Published: 2020

Includes: Supplemental data

Journal Articles

Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients

Ana Isabel Jiminez Ubieto, Yanira Heredia, Juan Manuel de la Rosa, Antonia Rodriguez Izquierdo, Laura Rufian, Jaime Carrillo, Ricardo Sanchez, Esther Onecha, PhD, Chongwu Wang, Pilar Sarandeses, María Poza, MD, Carmen Bárcena, Carlos Grande, Miguel A Canales, MD PhD, Inmaculada Rapado, PhD, Rosa Ayala, Miguel Gallardo, Joaquin Martinez-López, Santiago Barrio

Blood (2020) 136 (Supplement 1): 31–33.

https://doi.org/10.1182/blood-2020-139256

Published: 2020

Journal Articles

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Blood (2019) 134 (Supplement_1): 468.

https://doi.org/10.1182/blood-2019-128513

Published: 2019

Journal Articles

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Mariana Bastos-Oreiro, MD PhD, Nieves Lopez, Pilar Gomez, Liébana Marta, Laura LLorente, MD, Antonio Gutiérrez, EVA Domingo Domenech, PhD, Maria Jesus Vidal Maceñido, MD, Raquel Del Campo, Leyre Bento, Daniel Garcia, Miriam Santero, Jaime Perez De Oteyza, MD PhD, Belén Navarro, MD, Antonia Rodriguez Izquierdo, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4040.

https://doi.org/10.1182/blood-2019-125813

Published: 2019

Journal Articles

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Carmen Martinez, MD PhD, Cecilia Carpio, MD, Inmaculada Heras, Eduardo Ríos Herranz, MD, Joan Buch, Antonio Gutierrez, MD PhD, Samuel Romero, Izaskun Ceberio, Irene Garcia-Garcia, Antonia Rodriguez Izquierdo, PhD, Rosalia Alonso, Joan Bargay, MD PhD, Cristina Barrenetxea Lekue, PhD, Narvaez Javier, Manuel Espeso de Haro, MD, Luis Palomera, MD PhD, Ramon García-Sanz, MD PhD

Blood (2018) 132 (Supplement 1): 2936.

https://doi.org/10.1182/blood-2018-99-115774

Published: 2018

Journal Articles

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Thomas E. Witzig, MD, Lubomir Sokol, MD PhD, Eric D Jacobsen, MD, Won-Seog Kim, MD PhD, Francine M. Foss, MD, Ranjana H. Advani, MD, Jose Maria Roncero Vidal, MD, Ana Marin Niebla, PhD, Antonia Rodriguez Izquierdo, PhD, Raquel De Ona Navarrete, MD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Rufino Mondejar, PhD, Miguel A. Piris, PhD MD, Robert Curry, BA, MBA, Catherine Scholz, PharmD, Antonio Gualberto, PhD MD

Blood (2018) 132 (Supplement 1): 2937.

https://doi.org/10.1182/blood-2018-99-116277

Published: 2018

Journal Articles

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Nancy L. Bartlett, MD, Robert W. Chen, MD, Eva Domingo-Domenech, MD, Andres Forero-Torres, MD, Ramon Garcia-Sanz, MD PhD, Philippe Armand, MD PhD, Sumana Devata, MD, Antonia Rodriguez Izquierdo, MD, Izidore S. Lossos, MD, Craig B. Reeder, MD, Taimur Sher, MD, Cassandra Choe-Juliak, MD MS, Kim Prier, Sylvia Schwarz, PhD, Andras Strassz, MD, Leila Alland, MD, Stephen M. Ansell, MD PhD

Blood (2018) 132 (Supplement 1): 1620.

https://doi.org/10.1182/blood-2018-99-118506

Published: 2018

NARROW

The Addition of Brentuximab Vedotin to ESHAP Significantly Increases the Rate of Metabolic Complete Remissions Vs Chemotherapy Alone. in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma. Final Results of a Phase IIb Prospective Randomized Clinical Trial (BRESELIBET)

Effectiveness and Safety for Re-Treatment with Brentuximab-Vedotin in Patients with Relapsed/Refractory (R/R) CD30+ Malignancies: A Retrospective Medical Chart Review Study in Spain. the Believe Study. NCT:04998331

Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Potential Utility of Ctdna to Detect False Positive PET/CT in the Evaluation of Lymphoma Response

Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Incidence, Management and Outcome of Post-Transplant Lymphoproliferative Disease after 5797 Solid-Organ Transplants over a 30-Year Period in a Single Hospital

Utility of Bone Marrow Biopsies for Basal Stratification and Response Assessment in a Large Series of Real Life Follicular Lymphoma Patients

Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Usability and Performance Testing of Pointcheck™: A Noninvasive Neutropenia Screening Device for Chemotherapy Outpatients

Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial

Potential Utility of Circulating Tumor DNA Monitoring in Primary Mediastinal B-Cell Lymphoma Treated with R-DA-EPOCH

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma

Minimal Residual Disease Monitoring from Liquid Biopsy By Next Generation Sequencing in Follicular Lymphoma Patients

Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Nivolumab for Heavily Pretreated Relapsed/Refractory Hodgkin Lymphoma: Real-Life Experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only